Premium
In‐hospital outcomes of transcatheter mitral valve repair with Mitraclip in patients with pulmonary hypertension: Insights from the National Inpatient Sample
Author(s) -
Ahmed Abdelrahman,
Akintoye Emmanuel,
Adegbala Oluwole,
Yassin Ahmed,
Subahi Ahmed,
Bangura Lamin,
Abubakar Hossam,
Elder Mahir,
Shokr Mohamed,
Afonso Luis
Publication year - 2019
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.27997
Subject(s) - mitraclip , medicine , cardiogenic shock , pulmonary hypertension , pulmonary embolism , sepsis , mitral valve , cardiology , surgery , myocardial infarction
Background Periprocedural outcomes of transcatheter mitral valve repair (TMVR) with Mitraclip in patients with pulmonary hypertension (PH) are not well studied. Methods Patients who underwent TMVR with Mitraclip between 2011 and 2015 were identified using the National Inpatient Sample (NIS). All missing variables were excluded from the analysis and therefore, complete case analysis was performed. Results A total of 1,037 patients underwent TMVR with Mitraclip between 2011 and 2015. The prevalence of PH in these patients was 32.6%. In‐hospital outcomes were compared between PH group and non‐PH group. Inpatient mortality after TMVR was similar between the two groups (3.2% vs. 2.1%, OR 1.57, P = 0.335). There was no statistical significance between the two groups in the rates of hemorrhage requiring transfusion (8.5% vs. 7.2%, OR 1.17, P = 0.587), cardiogenic shock (4.4% vs. 4.5%, OR 0.98, P = 0.951), acute respiratory failure (15.2% vs. 13.1%, OR 1.23, P = 0.460), postoperative sepsis (2.75% vs. 3.9%, OR 0.66, P = 0.340), postoperative deep vein thrombosis or pulmonary embolism (2.7% vs. 3.9%, OR 1.98, P = 0.348). In addition, non‐routine home discharge, median hospital cost and length of stay were similar between the two groups. Conclusion Pre‐existing PH in patients undergoing TMVR with Mitraclip does not adversely affect in‐hospital outcomes in this cohort of patients. Therefore, PH does not carry a prohibitive risk in selecting patients for Mitraclip procedure.